RedHill Biopharma Ltd. Board of Directors

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Mr. Dror Ben-Asher

Mr. Dror Ben-Asher

Co-Founder, Chairman & CEO

Mr. Guy Goldberg J.D.

Mr. Guy Goldberg J.D.

Chief Business Officer

Mr. Razi Ingber

Mr. Razi Ingber

Chief Financial Officer

Mr. Adi Frish

Mr. Adi Frish

Chief Corporate & Business Development Officer

Mr. Rick D. Scruggs

Mr. Rick D. Scruggs

Chief Commercial Officer, President of RedHill Biopharma Inc. & Director

Ms. Alexandra Okmian

Ms. Alexandra Okmian

Senior Business Development & Investor Relations Manager

Dr. Reza Fathi Ph.D.

Dr. Reza Fathi Ph.D.

Senior Vice President of Research & Development

Ms. Patricia Anderson B.Sc. RAC

Ms. Patricia Anderson B.Sc. RAC

Senior Vice President of Regulatory Affairs

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.